A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients
Status:
Completed
Trial end date:
2020-08-11
Target enrollment:
Participant gender:
Summary
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in
Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected
Patients